ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...

Sdílet
Vložit
  • čas přidán 4. 06. 2022
  • Recorded @ ASCO Annual Meeting Press Conference, June 5.
  • Věda a technologie

Komentáře • 2

  • @Lisa_5591
    @Lisa_5591 Před rokem

    So curious if this will used in early stage Hormone positive and HER2 low breast cancer.

  • @stevenseidner7506
    @stevenseidner7506 Před 2 lety

    Should I avoid certain foods or is fasting recommended before treatment?